Physician profile

Lisa C Walker

Dermatology · San Antonio, TX

NPI 1578571816

$25,838.29

in general payments reported to CMS, 2019-2025

44 companies · $4,635 in 2025

The $4,635 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$14,347.86
Consulting Fee$3,250.00
Education$99.85

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ucb, INC. $4,320.90 2019-2025 Bimzelx
Abbvie INC. $4,278.04 2019-2025 Skyrizi, Rinvoq
Genzyme Corporation $1,760.98 2019-2025
Lilly USA, LLC $1,609.44 2019-2025 Taltz, Olumiant, Ebglyss
E.R. Squibb & Sons, L.L.C. $1,311.43 2022-2025 Sotyktu
Janssen Biotech, INC. $1,254.23 2019-2025 Tremfya
Galderma Laboratories, L.P. $1,223.29 2019-2025 Nemluvio, Aklief, Twyneo
Regeneron Healthcare Solutions, INC. $1,116.61 2019-2025 Dupixent, Libtayo
Janssen Scientific Affairs, LLC $1,089.65 2019-2025 Tremfya
Arcutis Biotherapeutics, INC. $872.51 2023-2025 Zoryve
Amgen INC. $721.85 2022-2025 Otezla, Otezla
Pfizer INC. $694.09 2022-2025
Ortho Dermatologics, A Division of Bausch Health US, LLC $693.62 2019-2025 Siliq, Cabtreo, Arazlo
Incyte Corporation $681.99 2022-2025 Opzelura
Sun Pharmaceutical Industries INC. $605.66 2019-2025 Absorica Ld, Winlevi, Ilumya
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Vyne Pharmaceuticals INC. $430.92 2020-2021
Dermavant Sciences, INC. $423.48 2023-2024 Vtama
Novartis Pharmaceuticals Corporation $420.43 2019-2025
Almirall LLC $321.47 2019-2023 Klisyri
Leo Pharma INC. $318.13 2019-2025 Adbry, Spevigo
Biofrontera INC. $196.87 2019-2025 Ameluz, Xepi, Bf-Rhodoled
Helsinn Therapeutics (U.S.), INC. $188.50 2019-2023 Valchlor
Boehringer Ingelheim Pharmaceuticals, INC. $175.60 2023-2025 Spevigo
Journey Medical Corporation $149.67 2022
Revance Therapeutics, INC. $147.96 2024 Daxi
Allergan, INC. $137.41 2020
Aclaris Therapeutics, INC. $124.98 2019
Glaxosmithkline, LLC. $107.96 2021
Paratek Pharmaceuticals, INC. $96.12 2022
Kci USA, INC. $62.50 2019
Tactile Systems Technology INC $42.55 2021-2025 Flexitouch Plus, Nimbl
Nabriva Therapeutics, Plc $37.42 2022
Mayne Pharma Commercial LLC $33.31 2019-2022
Krystal Biotech INC $27.20 2024 Vyjuvek
Integra Lifesciences Corporation $21.77 2025 Integra, Primatrix, Integra Dermal Regeneration Template
Cipher Pharmaceuticals US LLC $20.46 2025 Spinosad, Natroba
Sientra, INC. $19.71 2020
Kyowa Kirin, INC. $18.64 2022
Acera Surgical, INC. $18.38 2022
Kerecis Limited $15.82 2021
Celgene Corporation $13.46 2019
Mylan Pharmaceuticals INC. $11.95 2019
Genentech USA, INC. $11.09 2019
Organon LLC $10.24 2025

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lisa C Walker

$25,838.29

in general payments reported 2019-2025

Years
2019-2025
Top company
Ucb, INC.
Context
The $4,635 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).

https://glasscript.com/doctor/161844/lisa-c-walker

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.